News Releases Keyword Search Year None20212020201920182017201620152014 Apr 14, 2021 Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting Mar 29, 2021 Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I Mar 22, 2021 Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency Mar 09, 2021 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I Feb 25, 2021 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results Feb 18, 2021 Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Jan 11, 2021 Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline Jan 06, 2021 Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None20212020201920182017201620152014 Apr 14, 2021 Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting Mar 29, 2021 Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I Mar 22, 2021 Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency Mar 09, 2021 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I Feb 25, 2021 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results Feb 18, 2021 Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Jan 11, 2021 Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline Jan 06, 2021 Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
Apr 14, 2021 Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting
Mar 29, 2021 Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I
Mar 22, 2021 Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency
Mar 09, 2021 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I
Feb 25, 2021 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
Jan 11, 2021 Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline
Jan 06, 2021 Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
